Expressions of Putative Cancer Stem Cell Markers, CD44 and CD133, are Correlated with Pathological Tumour Stage in Gastric Adenocarcinoma

Düzcü, Selma Erdoğan; Astarci, Hesna Muzeyyen; Tunç, Nur; Boran, Çetin

doi:10.29271/jcpsp.2021.05.553

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oct4, Nanog, and Ascl2 are the main genes for intestinal stem cells to maintain self-renewal and cell dedifferentiation 32. CD133, CD44, and ALDH are critical surface markers in cancer stem cells [ 19 , 32 ]. In this study, we found that CSCs derived from CRCs have increased expression levels of stemness genes and tumor stem cell surface markers.…”

Section: Discussionmentioning

confidence: 99%

AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling

Yuan

Yang

et al. 2023

Stem Cells International

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are the core factors leading to recurrence, insensitivity to radiotherapy and chemotherapy, and immunotherapy resistance in patients with colorectal cancer. AT7867, a potent oral AKT inhibitor, was found to have antitumor activity in colorectal cancer; however, the effect on colorectal cancer stem cells is still unclear. This study was conducted to clarify the molecular mechanism underlying the CSC growth inhibitory effects of AT7867. We cultured colorectal cancer cells (CRCs) in a serum-free medium and enriched colorectal cancer stem cells. Subsequently, the effects of AT7867 on CSCs were analyzed by CCK-8, colony formation, flow cytometry, and immunofluorescence assays. The results indicated that AT7867 induces G2/M phase arrest and cell apoptosis in cancer stem cells. Subsequently, we identified Ascl2 as the main gene affecting the stemness of colorectal cancer in AT7867 by RNA sequencing. The current study showed that Ascl2 is involved in the metastasis, invasion, and proliferation of CRCs. The next experiments demonstrated that overexpression of Ascl2 did affect the therapeutic effect of AT7867 on CRC stemness. Furthermore, compared with other Akt inhibitors, AT7867 could promote the differentiation of colorectal cancer stem cells. Thus, AT7867 might be a potential antitumor drug candidate to treat CRC by targeting CSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling

Yuan

Yang

et al. 2023

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Cancer stem cells (CSCs) are characterized by self-renewal, pluripotency, and expression of stem cell markers, which can increase the malignant progression of the tumor [ 2 , 4 ]. Studies have shown that CSCs exist in cervix cancer, and their potential stem cell markers include CD133, ALDH1, CD49, OPN or SOX2 [ 5 ]. How to target stem cell markers and inhibit CSC characteristics of cervix cancer is an urgent problem needed to be addressed to improve the prognosis of patients with advanced cervix cancer [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of Eukaryotic translation initiation factor 3D induces stem cell-like properties and metastasis in cervix cancer by activating FAK through inhibiting degradation of GRP78

Zhong¹,

Lan

2022

Bioengineered

View full text Add to dashboard Cite

Cervix cancer (CC) is the most common gynecological malignancy and the leading cause of morbidity among women worldwide. Previous study indicated that cancer stem cells (CSCs) existed in cervix cancer, and suppressing CSC characteristics of cervix cancer is needed to combat this disease. Eukaryotic translation initiation factor 3 (EIF3) is one of the most complex eukaryotic translation initiation factors containing 13 subunits (EIF3A-EIF3M) and it regulates eukaryotic translation. One member of EIF3, EIF3D, plays a role in the progression and development of multiple tumors. However, its possible role in cervix cancer progression is still unclear. In this study, we found the high EIF3D expression in human cervix cancer tissues. We further found that downregulation of EIF3D suppressed the proliferation and motility of cervix cancer cells. Furthermore, its downregulation restrained the stem cell-like properties of cervix cancer cells. Mechanically, we found that EIF3D promoted FAK activation through GRP78 in cervix cancer cells, thus contributing to the progression of cervix cancer. Therefore our results suggested that EIF3D could serve as a promising target of cervix cancer.

show abstract

Comparison of human epidermal growth factor receptor 2 and cancer stem cell markers like CD44 and CD133 expressions with clinicopathological parameters in gastric cancer

GECER

Büyükpınarbaşılı

Turna

et al. 2023

The European Research Journal

View full text Add to dashboard Cite

Objectives: Gastric carcinoma (GC) is the fourth most common cause of cancer-related tumor deaths worldwide. The prognostic significance of CD44, CD133 and human epidermal growth factor receptor 2 (HER2) expression in GC remains controversial. Therefore, we aimed to investigate the relationship of CD44, CD133 and HER2 expression with clinicopathological features in metastatic and non-metastatic GC patients. Methods: A total of 139 patients with GC (68 with metastasis, 71 without metastasis) diagnosed were retrospectively analyzed. CD44 and CD133 expression were determined by immunohistochemical method in all cases. In addition, HER2 overexpression of the tumor was evaluated in patients with metastatic GC. Results: The CD133 positivity rate was 90.6% (n = 126) when all cases were considered, and that for CD44 was 84.9% (n = 118). There was no difference in CD133 and CD44 positivity (intensity or density) rates and between the total scores of metastatic and non-metastatic patients with GC (p > 0.05). HER2 positivity in metastatic cases was detected in 49 (70.1%) patients by immunohistochemical method. No correlation was found between CD133 total score and age, tumor size or depth, and HER2 scores in metastatic or non-metastatic cases (p > 0.05). In the correlation analyzes performed with CD44 scores, only a borderline significant correlation was found between CD44 scores and tumor size (r:0.175; p = 0.047) in non-metastatic cases. Conclusions: We demonstrated associations between CD44/CD133 expression and histological grade in all patients, between CD44 and tumor size in non-metastatic patients, and between HER2 and intestinal type (Lauren) in metastatic patients. The results of this study need to be confirmed by multicenter studies including large case series.

show abstract

Expressions of Putative Cancer Stem Cell Markers, CD44 and CD133, are Correlated with Pathological Tumour Stage in Gastric Adenocarcinoma

Abstract: Objective: To analyse partial and total gastrectomy specimen in items of immunohistochemical staining of the stem cell CD44 and CD133; and to determine their relationship to pathological stage, other clinicopathological prognostic parameters, and their predictive value.

Cited by 3 publications

References 3 publications

AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling

AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling

Overexpression of Eukaryotic translation initiation factor 3D induces stem cell-like properties and metastasis in cervix cancer by activating FAK through inhibiting degradation of GRP78

Comparison of human epidermal growth factor receptor 2 and cancer stem cell markers like CD44 and CD133 expressions with clinicopathological parameters in gastric cancer

Contact Info

Product

Resources

About